194 related articles for article (PubMed ID: 18444869)
1. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
McComsey GA; Lo Re V; O'Riordan M; Walker UA; Lebrecht D; Baron E; Mounzer K; Frank I
Clin Infect Dis; 2008 Apr; 46(8):1290-6. PubMed ID: 18444869
[TBL] [Abstract][Full Text] [Related]
2. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
[TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
John M; McKinnon EJ; James IR; Nolan DA; Herrmann SE; Moore CB; White AJ; Mallal SA
J Acquir Immune Defic Syndr; 2003 May; 33(1):29-33. PubMed ID: 12792352
[TBL] [Abstract][Full Text] [Related]
4. The effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: answers and questions.
Wanke C
Clin Infect Dis; 2008 Apr; 46(8):1297-8. PubMed ID: 18444870
[No Abstract] [Full Text] [Related]
5. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
[TBL] [Abstract][Full Text] [Related]
6. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
Carr A; Workman C; Smith DE; Hoy J; Hudson J; Doong N; Martin A; Amin J; Freund J; Law M; Cooper DA;
JAMA; 2002 Jul; 288(2):207-15. PubMed ID: 12095385
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.
van der Valk M; Casula M; Weverlingz GJ; van Kuijk K; van Eck-Smit B; Hulsebosch HJ; Nieuwkerk P; van Eeden A; Brinkman K; Lange J; de Ronde A; Reiss P
Antivir Ther; 2004 Jun; 9(3):385-93. PubMed ID: 15259901
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Gerschenson M; Kim C; Berzins B; Taiwo B; Libutti DE; Choi J; Chen D; Weinstein J; Shore J; da Silva B; Belsey E; McComsey GA; Murphy RL
J Antimicrob Chemother; 2009 Jun; 63(6):1244-50. PubMed ID: 19321503
[TBL] [Abstract][Full Text] [Related]
9. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
McComsey GA; Paulsen DM; Lonergan JT; Hessenthaler SM; Hoppel CL; Williams VC; Fisher RL; Cherry CL; White-Owen C; Thompson KA; Ross ST; Hernandez JE; Ross LL
AIDS; 2005 Jan; 19(1):15-23. PubMed ID: 15627029
[TBL] [Abstract][Full Text] [Related]
10. A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.
Menezes CN; Crowther NJ; Duarte R; Van Amsterdam D; Evans D; Dickens C; Dix-Peek T; Rassool M; Prinsloo A; Raal F; Sanne I
HIV Med; 2014 Jan; 15(1):3-12. PubMed ID: 23980620
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.
McComsey GA; O'Riordan M; Choi J; Libutti D; Rowe D; Storer N; Harrill D; Gerschenson M
Antivir Ther; 2012; 17(2):347-53. PubMed ID: 22293126
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy.
Casula M; Weverling GJ; Wit FW; Timmermans EC; Stek M; Lange JM; Reiss P
J Infect Dis; 2005 Nov; 192(10):1794-800. PubMed ID: 16235179
[TBL] [Abstract][Full Text] [Related]
13. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood mitochondrial DNA/nuclear DNA (mtDNA/nDNA) ratio as a marker of mitochondrial toxicities of stavudine containing antiretroviral therapy in HIV-infected Malawian patients.
Kampira E; Dzobo K; Kumwenda J; van Oosterhout JJ; Parker MI; Dandara C
OMICS; 2014 Jul; 18(7):438-45. PubMed ID: 24816082
[TBL] [Abstract][Full Text] [Related]
15. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
Rosso R; Nasi M; Di Biagio A; Repetto E; Dentone C; Pinti M; Nemes E; Ferraresi R; Mussini C; Esposito R; Viscoli C; Cossarizza A
Pediatr Infect Dis J; 2008 Jan; 27(1):17-21. PubMed ID: 18162932
[TBL] [Abstract][Full Text] [Related]
16. Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers.
ter Hofstede HJ; Willems HL; Koopmans PP
J Clin Virol; 2004 Jan; 29(1):44-50. PubMed ID: 14675869
[TBL] [Abstract][Full Text] [Related]
17. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial.
Menezes CN; Duarte R; Dickens C; Dix-Peek T; Van Amsterdam D; John MA; Ive P; Maskew M; Macphail P; Fox MP; Raal F; Sanne I; Crowther NJ
HIV Med; 2013 Apr; 14(4):217-25. PubMed ID: 23036096
[TBL] [Abstract][Full Text] [Related]
18. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
Martin A; Smith DE; Carr A; Ringland C; Amin J; Emery S; Hoy J; Workman C; Doong N; Freund J; Cooper DA;
AIDS; 2004 Apr; 18(7):1029-36. PubMed ID: 15096806
[TBL] [Abstract][Full Text] [Related]
19. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.
Viganò A; Brambilla P; Cafarelli L; Giacomet V; Borgonovo S; Zamproni I; Zuccotti G; Mora S
Antivir Ther; 2007; 12(3):297-302. PubMed ID: 17591019
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
